EUVIMEDEUVIMED entdecken
Open Access

Cost of Exempting Sole Orphan Drugs From Medicare Negotiation

Matthew Vogel, Olivia Zhao, William B Feldman, Amitabh Chandra, Aaron S Kesselheim, Benjamin N Rome

JAMA Internal Medicine · 2024

DOI: 10.1001/jamainternmed.2023.6293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, 2024. Verfasst von Matthew Vogel und 5 weiteren Autor:innen. Beteiligte Einrichtung: John F. Kennedy School of Government, Harvard University, Cambridge, Massachusetts. Hauptthemen laut MEDLINE: Medicare, Orphan Drug Production. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.

Objective

To estimate Medicare spending and global revenues for drugs that might have been exempt from negotiation from 2012 to 2021. Design, Setting, and Participants This cross-sectional study analyzed drugs that met the IRA threshold for price negotiation (Medicare spending >$200 million/y) in any year from 2012 to 2021 and had an Orphan Drug Act designation. We stratified drugs into 4 mutually exclusive categories: approved for a single rare disease (sole orphan), approved for multiple rare diseases (multiorphan), initially approved for a rare disease and subsequently approved for a nonrare disease (orphan first), and initially approved for a nonrare disease and subsequently approved for a rare disease (non–orphan first). Outcomes The primary outcomes were the number of sole orphan drugs, estimated Medicare spending on those drugs from 2012 to 2021, and global revenue since launch.

Results

Among 282 drugs, 95 (34%) were approved to treat at least 1 rare disease, including 25 sole orphan drugs (26%), 20 multiorphan drugs (21%), 13 orphan first drugs (14%), and 37 non–orphan first drugs (39%). From 2012 to 2021, Medicare spending on sole orphan drugs increased from $3.4 billion to $10.0 billion. Each year, a median (IQR) of $2.5 ($1.9-$2.6) billion in Medicare spending would have been excluded from price negotiation because of the sole orphan exemption. The cumulative global revenue of the median (IQR) sole orphan drug was $11 ($6.6-$19.2) billion. Conclusions and Relevance The sole orphan exemption will exclude billions of dollars of Medicare drug spending from price negotiation. The high level of global revenues achieved by these drugs, however, suggests that special exemption is unnecessary for them to achieve financial success. Congress could consider removing the sole orphan exemption to obtain additional savings for patients and taxpayers and to eliminate any potential disincentive for developing additional indications for these drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicareOrphan Drug ProductionHumansAgedUnited StatesRare DiseasesCross-Sectional StudiesNegotiatingDrug Costs

Autor:innen und Institutionen

  • John F. Kennedy School of Government, Harvard University, Cambridge, Massachusetts.
  • Harvard Business School, Boston, Massachusetts.
  • Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Vogel, M., Zhao, O., Feldman, W. B., Chandra, A., Kesselheim, A. S., & Rome, B. N. (2024). Cost of Exempting Sole Orphan Drugs From Medicare Negotiation. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2023.6293

Vancouver

Vogel M, Zhao O, Feldman WB, Chandra A, Kesselheim AS, Rome BN. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation. JAMA Internal Medicine. 2024. doi:10.1001/jamainternmed.2023.6293

BibTeX
@article{Vogel2024,
  author = {Vogel, Matthew and Zhao, Olivia and Feldman, William B and Chandra, Amitabh and Kesselheim, Aaron S and Rome, Benjamin N},
  title = {Cost of Exempting Sole Orphan Drugs From Medicare Negotiation},
  journal = {JAMA Internal Medicine},
  year = {2024},
  doi = {10.1001/jamainternmed.2023.6293}
}
Kostenlos starten →